New Genes in the Carcinogenesis of Colorectal Cancer

Colo-rectal Cancer Clinical Trial

Official title:

Investigating the Role of SPG20,STK31 Genes in the Carcinogenesis of Colorectal Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03261752
• Other study ID #: CRC
• Status: Not yet recruiting
• Start date: October 1, 2018
• Est. completion date: September 2019

Study information

• Verified date: July 2018
• Source: Assiut University
• Contact: mariana anwar, M.st
• Phone: 01012944965
• Email: mariana.10[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Colo rectal cancer is one of the greatest ,mutual malignancies worldwide ,accounting for an estimated 1.3 million new cases and >500,000 mortality ⁄ year . is the fourth leading cause of cancer-associated mortality worldwide with speedily ,cumulative ,occurrence rate in the worldwide

Description:

colo rectal cancer represents a global and local problem, as it is one of the commonest types of cancer all over the world. Globally, Colo rectal cancer in women (9.2% of diagnoses) it is the second most common cause of cancer . it is the third most common in men (10.0%). After lung, stomach, and liver cancer it is the fourth most common cause of cancer death.

Cancer is a multistep procedure resulting from an ongoing accretion of genetic and epigenetic fluctuations to the genome.

Spartin is a protein that in humans is encoded by the SPG20 gene. This protein may be involved in endosomal trafficking, microtubule dynamics, or both functions. Aberrant promoter methylation of genes is a common epigenetic alteration in colo rectal cancer .

This has stimulated the prospect to implement a dependable, reasonable and simple approach for Colo rectal detection . The SPG20 gene is situated in chromosome band 13q13.3; the SPG20 gene converts the spartin protein, which is a multi functional protein that has formerly been recognized to be complicated in intra cellular epidermal growth factor receptor trading , The serine-threonine kinase 31 (STK31) gene was initially identified through cDNA subtraction as a testis-specific protein kinase gene expressed in mouse spermatogonia . Recently, STK31 has been described as a novel cancer testis (CT) antigen, highly expressed in Gastrointestinal cancer cells (colo rectal, gastric and esophageal cancer), while restricted to testis and fetal brain in normal tissues .

It was found that SPG20 is mutated in Troy er syndrome, an hereditary spastic paraplegia

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 62
• Est. completion date: September 2019
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 65 Years

Eligibility

Inclusion Criteria:

• age between 35-65

• patient with colorectal cancer (at any stage)

• both sex included

Exclusion Criteria:

• pediatric patients

• patient with insufficient data

• cardiac patient

• pregnant women

Related Conditions & MeSH terms

• Carcinogenesis
• Colo-rectal Cancer
• Colorectal Neoplasms

Intervention

Diagnostic Test:
• blood sample
Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	detection of SPG20&STK31 genes	detection of SPG20&STK31 genes and prediction future treatment for colo-rectal cancer	5 months